Intellectual Property Rights Statement

Re: Measure Number 0129: Pediatric All-Condition Readmission Measure

This work was funded by the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Medicare & Medicaid Services (CMS) under the CHIPRA Pediatric Ouality Measures Program Centers of Excellence grant number U18 HS020513. AHRO, in accordance to CHIPRA 42 U.S.C. Section 1139A(b), and consistent with AHRQ's mandate to disseminate research results, 42 U.S.C. Section 299c-3, has a worldwide irrevocable license to use and permit others to use products and materials from the grant for government purposes which may include making the materials available for verification or replication by other researchers and making them available to the health care community and the public if such distribution would significantly increase access to a product and thereby produce substantial or valuable public health benefits. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the measures require a license agreement between the user and The Children's Hospital Corporation. Neither The Children's Hospital Corporation nor their members shall be responsible for any use of the Measures. The Children's Hospital Corporation makes no representations, warranties or endorsement about the quality of any organization or physician that uses or reports performance measures and The Children's Hospital Corporation has no liability to anyone who relies on such measures. The Children's Hospital Corporation's performance measures and specifications are not clinical guidelines and do not establish a standard of medical care.

Sincerely,

Mark A. Schuster, M.D., Ph.D., Principal Investigator

02 1 04 1 2014

Date